NGIO is now a separate company, just not listed. They file quarterly form 10s and operate independently. The deals for Covid should have been with NGIO not GNBT. NGIO should have rec’d the $2.65M, and supposedly the $5M, to be used to develop vaccines. NGIO should no longer be dependent on GNBT since , per Joe in recent (well somewhat recent in GNBT terms), NGIO has all the funds they need to finish development with Bintai and China. If anything, GNBT is dependent on NGIO now and hence why they got the money. We need management that thinks NGIO and nothing else. Move the potential vaccine on without worrying about GNBT. We don’t have that. Hopefully we will someday, if we can get thru these potential vaccines that we will hear about one day.
(4)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.